Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Stüve

Showing results (11-20 of 200) with videos related to

Pageof 20
Sort By:
Nature Reviews. Neurology|May 21, 2014
Multiple sclerosis: Natalizumab to fingolimod--the washout whitewashMartin Stangel, Olaf Stüve
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2017
Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational NeuroimmunologyAfsaneh Shirani, Olaf Stüve
The New England Journal of Medicine|December 2, 2020
Sodium Phenylbutyrate-Taurursodiol for ALSJoachim Herz, Olaf Stüve
Drugs & Aging|April 3, 2010
Multiple sclerosis in the elderly patientAmer Awad, Olaf Stüve
Neurology|September 20, 2013
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve
Annals of Neurology|December 28, 2016
The major histocompatibility complex and antibody-mediated limbic encephalitisOlaf Stüve, Steven Vernino
The Lancet. Neurology|February 21, 2023
Extended-interval dosing of natalizumab in NOVAOlaf Stüve, Bastian Tugemann
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
Time to talk about timing--when to start, stop and change anti-migratory drugs in MSOlaf Stüve, Bernhard Hemmer
Therapeutic Advances in Neurological Disorders|April 2, 2021
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessmentNavid Manouchehri, Olaf Stüve
Neurology|May 31, 2015
Natalizumab to fingolimod: Questions answered, unanswered, and unaskedOlaf Stüve, Dennis Bourdette
Pageof 20

Showing results (11-20 of 200) with videos related to

Sort By:
Pageof 20
Nature Reviews. Neurology|May 21, 2014
Multiple sclerosis: Natalizumab to fingolimod--the washout whitewashMartin Stangel, Olaf Stüve
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2017
Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational NeuroimmunologyAfsaneh Shirani, Olaf Stüve
The New England Journal of Medicine|December 2, 2020
Sodium Phenylbutyrate-Taurursodiol for ALSJoachim Herz, Olaf Stüve
Drugs & Aging|April 3, 2010
Multiple sclerosis in the elderly patientAmer Awad, Olaf Stüve
Neurology|September 20, 2013
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve
Annals of Neurology|December 28, 2016
The major histocompatibility complex and antibody-mediated limbic encephalitisOlaf Stüve, Steven Vernino
The Lancet. Neurology|February 21, 2023
Extended-interval dosing of natalizumab in NOVAOlaf Stüve, Bastian Tugemann
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
Time to talk about timing--when to start, stop and change anti-migratory drugs in MSOlaf Stüve, Bernhard Hemmer
Therapeutic Advances in Neurological Disorders|April 2, 2021
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessmentNavid Manouchehri, Olaf Stüve
Neurology|May 31, 2015
Natalizumab to fingolimod: Questions answered, unanswered, and unaskedOlaf Stüve, Dennis Bourdette
Pageof 20